Air India has initiated mandatory testing for banned substances for all its pilots, effective immediately. This comprehensive screening program extends to pilots at its budget subsidiary, Air India Express, starting this Thursday.
This decision follows a recent incident on August 4 where a flight from Phuket to Delhi unexpectedly lost 91 metres in altitude. A preliminary report indicated the senior pilot had to retake a substance test, reportedly testing positive for marijuana. Seventeen passengers and crew members sustained injuries during this event.
The airline's new policy significantly surpasses current regulatory requirements, which mandate random drug testing for only 10% of pilots. This expanded testing is a direct response to the recent safety lapse and aims to rebuild trust among passengers and stakeholders. It also reflects a broader effort to address safety concerns within the airline's operations.
Air India stated in an internal memo, seen by the BBC, that it is "important to go further" in its testing efforts. The airline emphasized that this initiative, which exceeds regulatory standards, demonstrates its commitment to maintaining the highest levels of safety and professionalism. This proactive measure seeks to reassure the public and the aviation community.
The airline has been under intense scrutiny following a tragic crash in June 2025. That incident involved a flight from Ahmedabad to London, which crashed shortly after takeoff, resulting in 241 fatalities on board and 19 on the ground. Only one passenger survived the devastating accident, intensifying public and regulatory pressure on Air India's safety protocols.
These new tests will cover both banned substances and medications prohibited under aviation regulations. The screenings are being conducted at various locations, including Air India's academy, briefing centres, and offices, often alongside training sessions. This integrated approach ensures widespread compliance and reinforces the airline's safety culture.
The implications of this policy are significant for pilot employment and operational costs. Pilots who fail these tests face immediate removal from duties, as seen with the two pilots involved in the August 4 incident. This could lead to temporary pilot shortages and increased training expenses for new recruits or re-qualified personnel. The airline's reputation and financial stability are directly tied to its safety record, making this a critical investment.
For the broader aviation industry, Air India's move could set a new precedent for pilot screening standards globally. Other airlines might face pressure to review their own substance testing policies, potentially leading to higher operational costs across the sector. Regulators may also consider tightening existing rules in light of this development and the recent incidents.
Investors and market analysts will closely monitor Air India's ability to implement these new protocols effectively and maintain its flight schedule. Any disruptions or further safety incidents could negatively impact its stock performance and market valuation. The airline's new chief executive, Tewolde Gebremariam, formerly of Ethiopian Airlines, faces the immediate challenge of restoring confidence and ensuring operational integrity.
This enhanced testing regime represents a substantial financial and logistical commitment for Air India. It underscores the critical importance of human factors in aviation safety and the severe consequences of non-compliance. The airline's long-term success hinges on its ability to consistently uphold these stringent safety measures and regain public trust.